MA37829A1 - Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha - Google Patents

Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Info

Publication number
MA37829A1
MA37829A1 MA37829A MA37829A MA37829A1 MA 37829 A1 MA37829 A1 MA 37829A1 MA 37829 A MA37829 A MA 37829A MA 37829 A MA37829 A MA 37829A MA 37829 A1 MA37829 A1 MA 37829A1
Authority
MA
Morocco
Prior art keywords
inhibitor
egfr
optionally
raf
pharmaceutical combinations
Prior art date
Application number
MA37829A
Other languages
English (en)
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure Moutouh-De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37829(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37829A1 publication Critical patent/MA37829A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une combinaison pharmaceutique comprenant (a) un inhibiteur de b-raf, (b) un inhibiteur d'egfr et facultativement (c) un inhibiteur de pi3k ; les utilisations d'une telle combinaison dans le traitement de maladies de prolifération ; et des méthodes de traitement d'un sujet souffrant d'une maladie de prolifération comprenant l'administration d'une quantité thérapeutiquement efficace d'une telle combinaison.
MA37829A 2012-08-07 2015-02-04 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha MA37829A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (fr) 2012-08-07 2013-08-05 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Publications (1)

Publication Number Publication Date
MA37829A1 true MA37829A1 (fr) 2017-01-31

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37829A MA37829A1 (fr) 2012-08-07 2015-02-04 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Country Status (40)

Country Link
US (1) US9474754B2 (fr)
EP (2) EP3574904B1 (fr)
JP (3) JP6342396B2 (fr)
KR (1) KR102112885B1 (fr)
CN (1) CN104519887B (fr)
AR (1) AR092045A1 (fr)
AU (1) AU2013299841B8 (fr)
CA (1) CA2879548C (fr)
CL (1) CL2015000294A1 (fr)
CO (1) CO7200273A2 (fr)
CY (1) CY1122143T1 (fr)
DK (1) DK2882440T3 (fr)
EA (1) EA028420B1 (fr)
EC (1) ECSP15008695A (fr)
ES (1) ES2717911T3 (fr)
FI (1) FI3574904T3 (fr)
GT (1) GT201500025A (fr)
HK (1) HK1211831A1 (fr)
HR (1) HRP20190537T1 (fr)
HU (1) HUE042877T2 (fr)
IL (1) IL236934B (fr)
IN (1) IN2015DN00450A (fr)
JO (1) JOP20130236B1 (fr)
LT (1) LT2882440T (fr)
MA (1) MA37829A1 (fr)
MX (1) MX359403B (fr)
MY (1) MY176031A (fr)
NZ (1) NZ703940A (fr)
PE (2) PE20150673A1 (fr)
PH (1) PH12015500246A1 (fr)
PL (1) PL2882440T3 (fr)
PT (1) PT2882440T (fr)
RS (1) RS58734B1 (fr)
SG (1) SG11201500321YA (fr)
SI (1) SI2882440T1 (fr)
TN (1) TN2015000027A1 (fr)
TR (1) TR201904980T4 (fr)
TW (1) TWI607754B (fr)
UA (1) UA115786C2 (fr)
WO (1) WO2014025688A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6342396B2 (ja) * 2012-08-07 2018-06-13 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
DK2976106T3 (da) 2013-03-21 2021-06-14 Array Biopharma Inc Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
WO2015145388A2 (fr) * 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
EP3392348A3 (fr) * 2014-06-16 2018-11-21 Worldwide Innovative Network Procédé de sélection de trithérapie personnalisée pour le traitement du cancer
WO2016193955A1 (fr) * 2015-06-04 2016-12-08 Giorgio Stassi Combinaisons d'inhibiteurs de kinase pour le traitement du cancer colorectal
CN107921026A (zh) * 2015-08-28 2018-04-17 诺华股份有限公司 药物组合物包含(a)α‑同种型特异性PI3K抑制剂alpelisib(BYL719)和(b)AKT抑制剂,优选MK‑2206,afuresertib或uprosertib及其在治疗/预防癌症中的应用
WO2017037573A1 (fr) * 2015-08-28 2017-03-09 Novartis Ag Combinaison pharmaceutique comprenant l'inhibiteur de pi3k alpélisib et l'inhibiteur de b-raf dabrafénib ; l'utilisation de cette combinaison dans le traitement ou la prévention du cancer
WO2017066664A1 (fr) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Polythérapie comprenant un inhibiteur de raf pour le traitement du cancer colorectal
BR112018074941A2 (pt) * 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
EP3515446B1 (fr) 2016-09-19 2023-12-20 Novartis AG Combinaisons thérapeutiques comprenant un inhibiteur de raf et un inhibiteur d'erk
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
KR20200036880A (ko) * 2017-08-03 2020-04-07 노파르티스 아게 3세대 EGFR 타이로신 키나아제 억제제 및 Raf 억제제의 치료적 조합물
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (fr) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de la pi3k
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
US20250108051A1 (en) * 2022-01-27 2025-04-03 Tohoku University Therapeutic agent for cancer
CA3257280A1 (fr) 2022-05-25 2023-11-30 Msd International Gmbh Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
CN120359031A (zh) * 2022-09-26 2025-07-22 马布可尔公司 用于治疗癌症的b-raf抑制剂和抗egfr抗体的组合
WO2025003956A1 (fr) 2023-06-30 2025-01-02 Pfizer Inc. Formulations d'encorafénib à forte charge médicamenteuse
WO2025262686A1 (fr) * 2024-06-20 2025-12-26 Ilan Paz Dispositifs, systèmes et procédés pour l'administration optimisée et personnalisée de formes posologiques pour voie orale

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EA020022B1 (ru) 2007-04-10 2014-08-29 Экселиксис, Инк. Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
MY165154A (en) * 2009-08-24 2018-02-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AU2010307043C1 (en) * 2009-10-12 2014-03-13 Glaxosmithkline Llc Combination
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
TR201802943T4 (tr) * 2010-11-08 2018-03-21 Novartis Ag (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı.
CN104185631A (zh) 2011-11-10 2014-12-03 纪念斯隆-凯特琳癌症中心 用2-氨基-4H-萘并[1,2-b]吡喃-3-甲腈治疗卵巢癌
US11007194B2 (en) * 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
JP6342396B2 (ja) * 2012-08-07 2018-06-13 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬

Also Published As

Publication number Publication date
CN104519887B (zh) 2017-06-27
HK1211831A1 (zh) 2016-06-03
AU2013299841A8 (en) 2017-01-05
ES2717911T3 (es) 2019-06-26
US9474754B2 (en) 2016-10-25
TWI607754B (zh) 2017-12-11
AU2013299841B2 (en) 2016-11-24
BR112015002384A8 (pt) 2019-07-30
JOP20130236B1 (ar) 2021-08-17
EA201590332A1 (ru) 2015-06-30
PH12015500246B1 (en) 2015-03-30
IL236934B (en) 2018-11-29
JP6342396B2 (ja) 2018-06-13
EP3574904A1 (fr) 2019-12-04
BR112015002384A2 (pt) 2017-07-04
JP2015524472A (ja) 2015-08-24
LT2882440T (lt) 2019-04-25
IN2015DN00450A (fr) 2015-06-26
ECSP15008695A (es) 2019-03-29
KR20150040905A (ko) 2015-04-15
AR092045A1 (es) 2015-03-18
DK2882440T3 (da) 2019-05-06
WO2014025688A1 (fr) 2014-02-13
KR102112885B1 (ko) 2020-05-19
JP6595024B2 (ja) 2019-10-23
MY176031A (en) 2020-07-22
CO7200273A2 (es) 2015-02-27
PT2882440T (pt) 2019-04-23
JP6974669B2 (ja) 2021-12-01
AU2013299841A1 (en) 2015-02-12
TR201904980T4 (tr) 2019-05-21
PH12015500246A1 (en) 2015-03-30
MX359403B (es) 2018-09-26
SI2882440T1 (sl) 2019-05-31
UA115786C2 (uk) 2017-12-26
CY1122143T1 (el) 2020-11-25
EP2882440B1 (fr) 2019-02-27
CA2879548C (fr) 2020-07-21
HK1204976A1 (en) 2015-12-11
CN104519887A (zh) 2015-04-15
GT201500025A (es) 2017-09-28
CL2015000294A1 (es) 2015-05-08
NZ703940A (en) 2018-04-27
HRP20190537T1 (hr) 2019-06-28
AU2013299841B8 (en) 2017-01-05
FI3574904T3 (fi) 2026-05-07
EP3574904B1 (fr) 2026-03-04
RS58734B1 (sr) 2019-06-28
PL2882440T3 (pl) 2019-07-31
MX2015001732A (es) 2015-06-03
PE20191655A1 (es) 2019-11-07
PE20150673A1 (es) 2015-05-20
EA028420B1 (ru) 2017-11-30
JP2020019780A (ja) 2020-02-06
JP2018109022A (ja) 2018-07-12
EP2882440A1 (fr) 2015-06-17
US20150265616A1 (en) 2015-09-24
SG11201500321YA (en) 2015-04-29
TN2015000027A1 (en) 2016-06-29
CA2879548A1 (fr) 2014-02-13
HUE042877T2 (hu) 2019-07-29
TW201410247A (zh) 2014-03-16

Similar Documents

Publication Publication Date Title
EA201590332A1 (ru) Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA033448B1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MA44612B1 (fr) Méthodes de traitement de cancers pédiatriques
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201000990A1 (ru) Лечение дисменореи путем трансдермального введения нестероидных противовоспалительных лекарственных средств
EA201200443A1 (ru) Комбинированное лекарственное средство и способ лечения венозных церебральных дисциркуляций
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
MA35927B1 (fr) Polythérapie pour le traitement d'un cancer de l'ovaire
MA38056B1 (fr) Inhibiteurs de la tyrosine kinase de bruton